Free shipping on all orders over $ 500

GYKI-52466

Cat. No. M3279
GYKI-52466 Structure
Synonym:

GYKI52466

Size Price Availability
10mg USD 1600  USD1600 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Gyki-52466 is a 2, 3-bendiazepine compound. As an ionic glutamate receptor antagonist, gyki-52466 is a non-competitive AMPA receptor antagonist (IC50 values of AMPA-, Kainate - and NMDA induced responses are 10-20, ~450 and >>50 μM, respectively). Oral active anticonvulsant compounds and skeletal muscle relaxation compounds. Unlike conventional 4, 5-benzodiazepines, Gyki-52466 and related 2, 3-benzodiazepines do not act on gabA-A receptors. Like other AMPA receptor antagonists, GYki-52466 has anticonvulsant and neuroprotective properties.

Chemical Information
Molecular Weight 293.32
Formula C17H15N3O2
CAS Number 102771-26-6
Solubility (25°C) DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yuchan Yang, et al. Combined preconditioning with hypoxia and GYKI-52466 protects rats from cerebral ischemic injury by HIF-1α/eNOS pathway

[2] P K Nayak, et al. Low-dose GYKI-52466: prophylactic preconditioning confers long-term neuroprotection and functional recovery following hypoxic-ischaemic brain injury

[3] G de Sarro, et al. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice

[4] S D Donevan, et al. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses

[5] T H Johansen, et al. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors

Related GluR Products
PDZ1 Domain inhibitor peptide

PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95).

CALP1

CALP1 is a calmodulin (CaM) agonist (Kd of 88 µM) with binding to the CaM EF-hand/Ca2+-binding site.

NT 13

NT 13 (TPPT) is a tetrapeptide having the amino acid sequence L-threonyl-L-prolyl-L-prolyl-L-threonine amide.

Tat-NR2Baa

Tat-NR2BAA is the control peptide of Tat-NR2B9c, inactive.

VSGLNPSLWSIFGLQFILLWLVSGSRHYLW

VSGLNPSLWSIFGLQFILLWLVSGSRHYLW is a 30-amino-acid peptide mimicking the C-terminal domain of α2δ-1, termed as α2δ-1Tat peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: GYKI-52466, GYKI52466 supplier, GluR, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.